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Summary 
Glucocorticoid-dependent transcriptional enhancement is known to occur through the interaction 
of the glucocorticoid receptor (GR) with specific DNA response elements. In contrast, negative 
regulation of gene expression by this class of hormone is less well understood. Glucocorticoids 
are potent immunosuppressive agents acting primarily by inhibiting T  lymphocyte activation 
and lymphokine production. Interleukin 2 (IL-2) gene expression, a critical early event during 
T  lymphocyte activation, is inhibited in glucocorticoid-sensitive cells by hormone treatment. 
We have studied the mechanism of this inhibition. In transgenic mice carrying c-myc linked to 
the  II~2  enhancer,  mitogen-induced expression  of the  transgene is  inhibited  by concurrent 
glucocorticoid treatment, while a similar transgene construct driven by three copies of the binding 
site for nuclear factor of activated T  cells  is  not  inhibited.  Cotransfection experiments into 
glucocorticoid-insensitive jurkat cells show that the NH2 terminus of the glucocorticoid receptor 
is dispensible for inhibition of the IL-2 enhancer but that an intact DNA binding domain, although 
not necessarily binding to DNA, is required. Hybrid GRs containing the DNA binding domains 
of either the estrogen receptor (ER) or thyroid receptor, as well as the entire wild-type ER, 
all function as repressors of the IL-2 enhancer. We have localized the site of inhibition to two 
sequences located in the proximal half of the enhancer. These sequences bind a similar,  if not 
identical, inducible nuclear factor that has biologic characteristics that distinguish it from AP-1. 
The mechanism of IL2 inhibition likely involves direct interactions between the GR and this factor. 
G 
lucocorticoid hormones have widespread effects in a va- 
riety of target tissues. Many of these effects, both posi- 
tive and negative, are a result of specific alterations in gene 
expression. The positive actions are mediated through the 
interaction of hormone with specific soluble receptors present 
in  target  cells.  The  glucocorticoid  receptor  (GR) 1 is  a 
member of a superfamily of ligand-activated hormone receptors 
that  function as  transcriptional modulators (1).  Hormone 
receptor complexes bind to specific sequences (glucocorticoid- 
responsive elements [GILEs])  in the 5' flanking regions of 
target genes and alter transcriptional activity (2).  A  large 
number of genes are transcriptionally activated by the GR; 
and their GREs, effectively acting as inducible enhancers (3), 
have a strong sequence conservation. Although there is a con- 
siderable body of knowledge about how glucocorticoids ac- 
tivate gene expression, the major clinical uses exploit their 
growth inhibitory, immunosuppressive, and antiinflamma- 
tory actions, which are, by comparison, considerably less well 
I Abbreviations used in this paper: GR,  glucocorticoid  receptor; GRE, 
glucocorticoid-responsive  element;  LS, linker  scanner;  NF-AT,  nuclear  factor 
of activated  T cells; nt, nucleotide;  OAP, octamer-associated  protein; Tag, 
T antigen. 
understood. The antiinflammatory effects have been attrib- 
uted to the induction of a set of proteins called lipocortins, 
which  inhibit  phospholipase  A2  (4),  or  alternatively,  to 
direct inhibition of expression of inflammatory mediators such 
as IL-1 (5) or secreted proteases such as collagenase (6) and 
stromelysin (7).  In addition,  glucocorticoids participate in 
negative feedback loops, thus inhibiting expression of proopi- 
omelanocortin  (POMC)  (8),  and  have  adverse  effects on 
reproductive function by negative regulation of a variety of 
genes including prolactin (9), proliferin (10), and the chori- 
onic gonadotropin oe subunit (11). Negative transcriptional 
regulation of these genes has been postulated to occur via 
the interaction of the GR with negative GREs (nGREs) (9) 
located in their 5' flanking regions. These nGREs appear to 
be distinct from and not as highly conserved as GREs, and 
have been proposed to overlap binding sites for transcriptional 
activators on the DNA.  Recent studies, however, have de- 
scribed a mechanism whereby the GR interferes with the ac- 
tivity of the transcription factor AP-1 by direct protein-protein 
interactions (12-15). 
Disease states where T cell- and cytokine-mediated tissue 
damage predominates, including many examples of chronic 
inflammation, delayed hypersensitivity, and transplant rejec- 
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Volume 175  May 1992  1235-1245 tion, are also effectively treated with glucocorticoids.  We have 
studied the intracellular signaling pathways operative during 
the early phases of T  lymphocyte activation using the IL-2 
gene as a model system. T lymphocytes are activated by con- 
tact with specific antigen in conjunction with MHC mole- 
cules on the surface of APCs (for review, see reference  16). 
In addition, an accessory signal provided by APCs in the form 
of IL-1, IL-6, or IL-7 is needed for T cell activation (17-19). 
Critical events that occur during primary immune responses 
are proliferation of antigen-specific T  cells, differentiation, 
and cytokine production. IL-2 plays a central and early role 
in these processes, and inhibition of IL-2 production is there- 
fore likely to mediate a large number of glucocorticoid effects 
on immune function. Previous  studies have shown inhibi- 
tion of IL-2 production (20), IL-2 mRNA accumulation (21), 
and IL-2 transcription (22) after glucocorticoid treatment of 
T  ceils. Since addition of IL-2 to cultures of T  ceils stimu- 
lated in the presence of glucocorticoids overcomes  the inhi- 
bition of T  cell activation, it is likely that the major effect 
of the drug is to block ID2 production. To investigate the 
mechanism of transcriptional repression  of IL-2, we have ex- 
amined GR activity on functional regions of the IL-2  enhancer. 
In addition, we have studied functional domains of the GR 
needed for repression.  Our results help define a mechanism 
for glucocorticoid inhibition of IL-2 expression. 
Materials and Methods 
Cells and Culture.  Humanjurkat cells  and mouse LBRM T cell 
lymphoma  cells  were grown in RPMI 1640 supplemented  with 10% 
(vol/vol) heat-inactivated  FCS, 100 U/ml penicillin, and 100/~g/ml 
streptomycin in a 5%  CO2/95%  air humidified atmosphere. 
Plasmids.  Expression vectors for  the  mouse  glucocorticoid 
receptor and derivatives have, for the most part, been described 
as follows:  SV2Wrec and SV2NB5'rec (NB5') (23); A395 and A575 
(24); pGE and pGE9 (AEG) (25). The hybrid receptor (TR) con- 
taining the DNA binding domain of the human TR between the 
first and last conserved cysteine residues inserted into the vector 
pSV20.3Xrec was a gift of Lindsay Hinck (Syntex Research, Palo 
Alto, CA). The construct pJ3MOR, encoding the mouse estrogen 
receptor has been described (26). The plasmid pSV2neo has been 
described (27). Reporter constructs based on CAT: pIb2CAT, linker 
scanner (LS)-generated internal deletion mutants of the IL-2 en- 
hancer LS5 (ID 279/263), LS29 (ID 208/174), LS1 (ID 140/120), 
LS20 (ID 153/121), and the duplicated proximal Ib2 enhancer con- 
struct  DSCAT (BB), have all been previously described (28). 
MMTVCAT has been described (23) as has RSVCAT (29). Nu- 
clear factor of activated T ceils (NF-AT) p22-6 was constructed by 
Verweij (30) by inserting three copies of the NF-AT binding site 
(Ib2 sequences -286 to -257) into the XhoI site of p22-6, p22-6 
contains a minimal II.,2 promoter (sequences -294 to -72 deleted 
from pIL2CAT). Oct p22-6 was similarly  constructed by insertion 
of four copies of the Octl/OAP binding site (-65 to  -94) into 
the XhoI site of p22-6. The plasmids APCAT and the lacZ-based 
reporter constructs NFIL-2BZH, NFATZH, KBZH, and pIb2ZH 
have been described (31). OctZH was constructed by Jeff Riegel 
(Howard Hughes Medical Institute, Stanford,  CA) by inserting four 
copies of the Octl/OAP site (-65 to  -94) in place of the three 
NF-AT binding sites in NFATZH. 
Transfections and Stimulations.  Jurkat cells growing at a density 
of not greater than 106/ml were harvested by low-speed centrifu- 
gation and resuspended in growth medium at a density of 3  x 
107/ml. Plasmid DNAs,  10 #g of reporter construct, and 10/~g 
of receptor construct or pSV2neo in a total volume of 20/~1 10 
mM Tris (7.5), 1 mM EDTA, were added directly to 300/zl ('~107 
cells) of the concentrated cell suspension. This mixture was elec- 
troporated in a 0.4-cm cuvette with a gene pulser (Bio-Rad  Labora- 
tories, Richmond, CA) using 250 V and 960/zF capacitance. Cu- 
vettes were then gently agitated for 5 min and the cell mixtures 
resuspended in 12 ml complete growth medium. 
Stimulations were initiated after 40 h of growth using 2/~M 
ionomycin  (Calbiochem-Behring  Corp., San Diego, CA) dissolved  in 
DMSO and 10 ng/ml PMA (Sigma Chemical Co., St. Louis, MO) 
dissolved in  ethanol plus or minus  10 -6 M  dexamethasone or 
10-7 M estradiol dissolved  in ethanol. Stimulations were allowed 
to proceed for 8 h before analyzing reporter gene activity. To elim- 
inate errors due to differences in transfection efficiency,  different 
stimulation conditions for the same reporter/receptor combination 
were done on aliquots of ceUs taken from the same electroporation 
cuvette. The relevant data for these studies are the extent to which 
inducible reporter gene activity is inhibited by hormone treatment. 
The inclusion of a construct to normalize for transfection  efficiency 
has no effect on these data and was therefore not included except 
in experiments where the constitutive receptor, A575, was com- 
pared with the wild-type GR. These transfections included 2 #g 
of RSVCAT as an internal control. 
CAT/B-Galactosidase Assays.  CAT assays were carried out es- 
sentially  as described (32). Acetyl  coenzyme A was from Pharmacia 
Fine Chemicals (Piscataway, NJ)  and  14C-chloramphenicol (57 
mCi/mmol) from Amersham Corp. (Arlington Heights, IL). CAT 
assays were quantitated directly using a radionucleotide imaging 
system (Ambis Systems, San Diego, CA). ~-galactosidase  activity 
produced from the lacZ reporter gene was measured in triplicate 
200-/~1 aliquots of transfected cells using 4-methylumbelliferyl-13- 
D-galactoside (Sigma Chemical Co.) as a substrate as described (31), 
except that 150/zl of reaction mixture containing 0.6 mM sub- 
strate was added to the cell pellets, and incubations were allowed 
to proceed for 3 h at 37~  before stopping. Fluorescence at 460 
nm  was  measured using  355-nm excitation  with  a  Titertek 
fluoroscan II (Flow Labs, McLean, VA). 
Ribonuclease Protections.  Transgenic  mice used in these studies 
were established  by C. Verweij (Central Laboratory of the Nether- 
lands Red Cross) and E. Lacy (Sloan-Kettering Memorial Insti- 
tute). The T antigen carrying line, Tag8, has been described (30). 
This line expresses SV40 T antigen (Tag) under the control of three 
NF-AT binding sites  linked to the minimal Ib2 promoter. Tag tran- 
scripts are detected in spleen, thymus, and bone marrow cells only 
after stimulation with ionomycin and PMA. A second transgenic 
line was established that carries a single copy of the human c-myc 
gene driven by the human IL-2  promoter/enhancer sequences - 586 
to +47. The line used (no. 17) expresses c-myc transcripts in spleen 
and thymus only after mitogen stimulation (C. Verweij, E. Lacy, 
and G. Crabtree; unpublished results). 
Ribonuclease protection probes used were as follows. To detect 
endogenous routine Ib2 transcripts, a 160-bp SacI/HindlII  frag- 
ment excised from the plasmid pCD-Ib2 (provided by Frank Lee, 
DNAX, Palo Alto, CA) was cloned into the SacI/HindlII  sites 
of pBluescript KS(+) (Stratagene, La Jolla, CA). This construct 
was linearized with SacI and a 3zP-labeled transcript synthesized 
from the T3 promoter. The resulting 200-nucleotide (nt) probe 
protects a 160-nt fragment. To detect the c-myc transgene, a 350-nt 
probe was synthesized from the SP6 promoter using the plasmid 
pSP65Gal (33) linearized with PstI. This probe protects the 47 nt 
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tect the Tag transgene, a 272-bp PstI/HindlII fragment of the SV40 
Tag gene was cloned into pBluescript KS (-). This construct  was 
linearized with HindlII and used as a template for the synthesis 
of a 330-nt riboprobe from the T7 promoter. This probe protects 
272 nt of the Tag message. Spleen cells from 6-8-wk-old mice were 
prepared  as described (30) and  stimulated  for 3 h  with  2 #M 
ionomycin plus  10 ng/ml PMA. Dexamethasone  (10 -6 M) was 
added  at  the indicated  times before or during  the stimulation. 
Ribonuclease protection  using 5 #g of RNA per sample was per- 
formed as described (31, 34). For the Tag mice, RNA samples were 
incubated with both the mouse Ib2 and the Tag probes simultane- 
ously. RNA samples from the c-myc-expressing  mice was incubated 
with both the IL-2 and SP65Gal probes so that both protected bands 
appear in the same lane. Quantitation was done using the Ambis 
system as described for CAT assays. 
Electrophoretic  Mobility Shift Assays.  Small  scale nuclear extracts 
from jurkat and LBRM cells stimulated  for 3 h with 10 ng/ml 
PMA plus 2 #M ionomycin plus or minus 10 -6 M dexamethasone 
were made as described (33). Gel mobility shift assays used the fol- 
lowing oligonucleotides  as probes, competitors,  or both: AP-1, 
tcgaGTGACTCAGCGCGtcga  containing  the AP-1 binding  se- 
quence from the human metallothionein  enhancer (35); NFID2B, 
tcgaCAATTCCAAAGAGTCATCAGAAGAGGACtcga  containing 
1I.-2 sequences -134 to -159; octamer-associated protein (OAP), 
gtCTTTGAAAATATGTGTAATATgt containing  IL2  sequences 
-76 to  -100;  Oct/OAP, gatcTTTGAAAATATGTGTAATATG- 
TAAAACATTTTGgatc  containing  ID2 sequences -65 to  -97; 
NF-AT, gatcAAGGAGGAAAAACTGTTTCATGgatc  containing 
II.-2 sequences - 268 to - 288. nt in lower-case letters above repre- 
sent 5' overhanging ends that are filled in with Klenow when the 
double-stranded oligonucleotides are labeled for probes. Otherwise, 
the overhangs are not filled in. 
Gel mobility shifts were done as described (33) using 10 #g of 
jurkat or LBRM extract.  In all cases, proteins were preincubated 
with buffer, nonspecific competitor, and specific  competitor oligo- 
nucleotides where noted for 15-20 min before addition of the la- 
beled probe. Competitor oligonucleotides were used at 150-200- 
fold molar  excess over labeled probes.  Incubations  with labeled 
probes were done in a 20-#1 volume containing  10 mM "Iris (7.5), 
50 mM NaC1, 0.5 mM EDTA, 5% glycerol, and 1.7 #g of poly 
dldC. After 60 min at room temperature, samples were loaded on 
4.5%  polyacrylamide gels and run at room temperature. 
Results 
Dexamethasone Inhibits Both Endogenous 11_,2 and an 11_,2 
Enhancer-driven Transgene.  Previous studies have shown that 
negative regulation of I1:2 expression in the lymphoblastoid 
T cell line jurkat is, at least in part, transcriptional,  and I1:2 
sequences within  600 bp upstream  from the start  of tran- 
scription are implicated in mediating this repression (22). For 
our studies we felt it necessary to determine first whether 
this negative regulation could also be observed in splenic lym- 
phocytes.  We investigated this in transgenic  mice carrying 
a c-myc transgene driven from human I1:2 sequences  -586 
to  +47 (E.  Lacy a~d G.  Crabtree,  unpublished results).  In 
addition,  we wanted  to  test,  under  similar  circumstances, 
whether a construct responsive to only a single transcription 
factor essential for I1:2 gene activation,  NF-AT,  would be 
sensitive to negative regulation by the glucocorticoid dexa- 
methasone.  This was tested in a second transgenic line con- 
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taining  SV40 Tag driven by a minimal  I1:2 promoter  and 
a trimer of NF-AT binding sites (-257 to  -286) (30) (Fig. 
1 A). These mice express properly initiated messages in lym- 
phoid tissues only after mitogenic stimuli,  thus mimicking 
closely the expression of endogenous Ib2. The results shown 
in Fig.  1 B, lanes 1-7,  indicate that  the expression of the 
I1:2/c-myc fusion gene follows the expression of the endoge- 
nous murine I1:2 exactly. This confirms that sequences within 
600 bp of the start  of transcription  are sufficient for both 
activation-specific  expression  and  dexamethasone-induced 
repression of I1:2 gene activity. Repression of I1:2 message 
is not complete at 3 h (40-54% inhibition for both the I1:2 
and I1:2/c-myc  messages when dexamethasone is given 1 h 
before or at the time of activation), while reporter gene ac- 
tivity in transient expression assays can be much more exten- 
sively inhibited  (see below). This partial inhibition  of I1:2 
message production is evident even when looking at nuclear 
run-on  transcription  (22).  Some repression can still be ob- 
served when dexamethasone is given well after the time when 
I1:2 message is first detectable and after the time (~45 min) 
when inhibitors of protein synthesis no long abolish I1:2 in- 
duction (36).  This  suggests that  inhibition  can still occur 
after critical transcription factor synthesis, possibly by direct 
interactions between the GR and these factors and/or DNA. 
The results shown in Fig.  1 B, lanes 8-10,  using the NF- 
AT~Tag mice are quite different;  while Ib2 expression is again 
inhibited by 50%, the transgene is unaffected. This indicates 
that NF-AT is likely not the target for inhibition in splenocytes. 
The above results indicate that a fragment of the II~2 gene 
encompassing only 600 bp of upstream sequences can, when 
stably integrated into the genome, behave identically to the 
endogenous Ib2 gene. We next tested whether a smaller frag- 
ment of I1:2,  -325  to  +47, previously shown to contain 
the II:2 tissue- and activation-specific enhancer (37, 38), would 
confer negative regulation by dexamethasone. Fig. 1 C shows 
that  induction  of pID2CAT transfected into jurkat  cells  is 
almost completely abolished by dexamethasone  treatment, 
while a construct with three copies of NF-AT directing ex- 
pression of CAT appears relatively insensitive to hormone. 
In addition, the Ib2 enhancer construct in this transient ex- 
pression assay is inhibited to a greater extent than that found 
for endogenous  Ib2  or the I1:2/c-myc  transgene. 
Structural Requirements  of the  GR for  Negative  Regula- 
tion.  Domains of the GR important for transcriptional  ac- 
tivation have been well characterized  (24, 39).  We wanted 
first to test if the structural requirements of the GR needed 
for Ib2 repression were similar to those required for tran- 
scriptional activation. Our clone ofjurkat ceils is insensitive 
to glucocorticoids,  as Western blotting reveals little if any 
GR  protein,  and  a  transfected  glucocorticoid  responsive 
reporter construct, MMTVCAT, is not inducible upon dexa- 
methasone treatment in these ceils (data not shown). Cotrans- 
fection of the mouse GR expression vector pSV2Wrec results 
in an "o18-fold induction of MMTVCAT in jurkat cells (Fig. 
2).  When cotransfected with pI1:2CAT  (Figs.  2 and  1 c), 
wild-type GR is able to inhibit >80% of the normal induc- 
tion of the I1:2 enhancer,  indicating that a functional receptor 
protein is necessary for repression.  The control construct, Figure 1.  Repression of endogenous IL-2 and II.-2 en- 
hancer or NF-AT-driven  reporter genes in transgenic mice 
and jurkat cells. (A) Constructs used to generate trans- 
genic mice. Top shows c-myc  placed downstream of a 600- 
bp fragment of the human IF2 gene containing  the whole 
enhancer and promoter. Bottom shows SV40 T antigen 
driven from the minimal  I1,2 promoter with three copies 
of the binding site for NF-AT. (B) Kibonuclease protec- 
tion to detect endogenous murine II-2 (top) and the trans- 
genes Ig2/c-myc (lanes 1-7, bottom) and NF-AT/T-antigen 
(lanes 8-1I,  bottom). Isolated splenocytes were either not 
stimulated (lanes 2 and 9) or stimulated for 3 h with PMA 
and ionomycin  in the absence (lanes 3 and 10) or the pres- 
ence of dexamethasone added at the following times rela- 
tive to stimulus addition. Lane 4,  -1 h; lanes 5 and 11, 
0 h; lane 6,  +1 h, and lane 7,  +2 h. Lanes 1 and 8 are 
tRNA-containing control samples. (C) GR-defident jurkat 
cells were  transiently cotransfected  with  10  #g  of 
pSV2Wrec and either  10 #g of plL-2CAT or 10 #g of 
NF-AT p22-6 by electroporation.  Cells were treated for 
8 h with either solvent alone (nonstimulated,  N'), PMA 
plus ionomycin (stimulated, S), or PMA plus ionomycin 
plus dexamethasone (S + De'x). CAT activity was then as- 
sayed in whole cell extracts. 
pSV2neo, does not confer repression of plI~2CAT. An NH2- 
terminally truncated GR construct, A395, has little activity 
on MMTVCAT (Fig. 2) (24), however, it retains almost full 
capacity to repress plL-2CAT. These results indicate that the 
NH2-terminal half of the GR, while containing a transcrip- 
tional activation domain, is not necessary for negative regu- 
lation. This is analogous to previous findings with the chori- 
onic gonadotropin o~  subunit  (HCG)  gene  (40)  and  the 
coUagenase gene (14). 
The above result indicates that structural requirements of 
the  GR  needed for  repression  and  activation  may  differ 
significantly. A synthetic GR, where arginine 484 is mutated 
to histidine, is a very poor repressor (Fig. 2), indicating that 
an intact DNA binding domain is required for repression. 
Since this mutant is also defective in nuclear translocation 
(23, 41), this result does not necessarily indicate that DNA 
binding is required for repression. To further address this ques- 
tion, we tested three more constructs, each with a fully func- 
tional DNA binding domain, but whose target hormone- 
responsive  element specificity had been changed by DNA 
binding domain swaps with either thyroid receptor or es- 
trogen receptor (GE), or by two amino acid changes in the first 
zinc finger that changes the hormone-responsive element to 
that of the estrogen receptor (AEG).  These constructs acti- 
vate transcription from an estrogen-responsive element (GE, 
AEG)  (25) or thyroid-responsive element (TR) (L. Hinck, 
personal communication), but not from a glucocorticoid- 
responsive element, and therefore have different DNA binding 
specificities from that of the GR. We found that these hy- 
brid receptors also functioned as efficient repressors of Ib2 
enhancer activity (Fig.  2).  The fact that the construct GE 
represses only 40% as efficiently as wild-type GR is consis- 
tent with its 40% efficiency as compared with AEG for acti- 
vation of an ERECAT construct (25). These results do not 
favor a mechanism of repression involving direct contact of 
GR with DNA, as is the case for positive hormone-responsive 
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NB5' 
A 395 
TR 
z~ EG 
GE 
ER 
A 575 
DNA  ligand 
R484 ~H 
L--s4 # 7 -,-G 
G446 ->E 
Control  SV2neo 
IL2  MMTV 
%Inhibition  Relative 
Relative (Abs.)  %Activation  (Fold Ind.) 
100  (82.0)  100  (17.7) 
6  (5.2)  0  (0) 
92  (75.4)  6.5  (2.1) 
86  (70.4)  nd 
106  (86.7)  nd 
40  (33.2)  nd 
60  (49.0)  nd 
85  (69.6)  100  (1.3) 
o  (o)  o  (o) 
Figure  2.  Deletion and  mutation 
analysis of the GR. Various GR ex- 
pression constructs, wild-type  ER, or 
control SV2neo depicted on the left 
were cotransfected into GR-deficient 
jurkat cells  with plD2CAT as described 
in  Fig. 1  or  with  the  glucocorti- 
coid-responsive  reporter construct 
MMTVCAT. Cells  transfected  with pll~ 
2CAT were treated with PMA plus 
ionomycin  in the presence or absence 
of dexamethasone  as described in Fig. 
1 or with 10-7 M estradiol (for ER). 
MMTVCAT-transfected cells were 
treated with or without  dexamethasone 
for 8 h before  harvest  for CAT assays. 
The results  for pIL-2CAT  are shown  as 
absolute (Abs.) inhibition  of PMA plus 
ionomycin-induced  CAT activity  or rel- 
ative to the inhibition  produced  by the 
wild-type  (SV2l.Vrec)  construct.  The in- 
hibition by A575 was constitutive  and 
was calculated using RSVCAT as an 
internal control and plL-2ZH as the 
reporter. The results for MMTVCAT 
are shown  as fold  induction  of  CAT ac- 
tivity or relative  to the wild-type  con- 
struct. Not determined  (nd). The results 
represent the mean of two to six inde- 
pendent experiments. 
elements. We next investigated the function of the hormone 
binding domain in repression  of the II:2 enhancer by both 
changing and deletion of this region. Since a hybrid GR con- 
taining the ER DNA binding domain is a functional repressor, 
and the NH2-terminal half of the receptor is not necessary, 
we reasoned that the wild-type EK might also be an effective 
repressor  when suitably activated. Fig. 2 shows that the ER 
does function as a repressor, although only 60% as efficiently 
as the GR.. This repression  was not seen when cells trans- 
fected with the ER were treated with dexamethasone (data 
not shown). Deletion of a sufficient proportion of the hor- 
mone binding domain to produce the constitutive transcrip- 
tional activator, A575 (Fig. 2) (24), also results in a constitu- 
tive repressor of the I1:2 enhancer, which is only slightly less 
efficient that the wild-type GK. These results indicate that 
the specificity of the hormone binding domain is not critical 
and that, to a large extent, this domain is not necessary for 
repression. 
Repression of lL2 Occurs through More Than One Transc@- 
tion Factor Binding Site.  The above experiments demonstrated 
that an IL-2 enhancer containing only 325 bp of upstream 
sequence is able to mediate glucocorticoid repression.  Addi- 
tionally, GK structural requirements for I1:2 repression are 
similar to those found for repression of  Jun/AP-1 activity (14, 
40).  In  fact,  at  least  two  AP-l-like  sequences  have  been 
identified within the I1:2 enhancer at approximately  -147 
and  - 181 (42), the former of which lies within a function- 
ally important region (28).  To determine the site(s) medi- 
ating repression,  a series of deletion mutants of the I1:2 en- 
hancer was tested for repression  by a cotransfected GK in 
jurkat cells. Since the I1:2 enhancer is virtually silent in the 
absence of stimulation (36) (Fig.  1), and glucocorticoids in- 
hibit activation of the enhancer in response  to stimulatory 
signals, we focused our studies on previously identified func- 
tional regions of the enhancer. Deletion of the NF-AT binding 
site in LS5 leads to a construct that is highly repressible (Fig. 
3 A). This is consistent with data presented in Figs. 1 C and 
3 B, showing little repression through multimerized NF-AT 
sites. Deletion of a second purine-rich sequence  similar to 
the NF-AT site also has no effect on repression (LS1 in Fig. 
3 A). Two more deletions (LS29, which deletes the NFIL-2C 
[NFKB like] sequence and an AP-l-like sequence, and LS20, 
which deletes  the NFIL2B [also  AP-1  like]  sequence)  are 
repressed  to an extent similar to that of the wild-type en- 
hancer (Fig. 3 A). These results indicate that none of these 
sites alone are responsible  for GR repression  of the I1:2 en- 
hancer. Deletion of NFI1:2A (Octl/OAP) site leaves an en- 
hancer with so little ability to be activated (28) that repres- 
sion could not be tested in this construct. Duplication of the 
proximal half of the enhancer containing the NFI1:2A and 
NFI1:2B sites as in DSCAT (Fig. 3 A) results in an inducible 
construct that retains the wild-type ability to be repressed. 
We then used a series of constructs where multimerized 
individual sites from the IL-2 enhancer are linked to a min- 
imal I1:2 promoter. The results of these experiments using 
identical constructs driving either CAT or lacZ are presented 
in Fig. 3 B. While a construct driven by three NFKB binding 
sites shows no repression,  two sites, NFI1:2A (Oct p22-6 
and OctZH) and NFI1:2B (NFI1:2BZH and APCAT), show 
>50% repression.  It is likely that the deletion mutant LS20, 
which lacks the NFIL2B site (see above), remains repressible 
because it still contains an intact NFI1:2A site. These results 
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Figure 3.  Mapping the site of GR 
inhibition in the Ib2 enhancer. (.4) De- 
letion  analysis of the  11:2 enhancer. 
Linker-scanner generated internal dele- 
tions of the I1:2 enhancer,  with each 
retaining significant inducibility but in 
general somewhat lower than the wild- 
type enhancer  (28); or (B) multimer- 
ized factor binding sites from the I1:2 
enhancer  or NF~B site from ~ light 
chain enhancer linked to the I1:2 pro- 
moter and  either CAT or lacZ were 
cotransfected with 10 #g of pSV2Wrec 
into jurkat cells as described in Fig. I. 
8-h stimulations  with PMA plus iono- 
mycin  in  the presence  or  absence of 
dexamethasone were followed by anal- 
ysis of CAT or B-gahctosidase activity. 
Results are presented as percent inhibi- 
tion of inducible CAT/B-galactosidase 
activity in absolute (Abs.) terms and rel- 
ative  to  the complete enhancer.  The 
results represent the mean of from two 
to  seven independent  experiments. 
Numbers above the constructs  are rela- 
tive to the start  of II--2 transcription. 
Shaded boxes represent functional areas 
of the enhancer, named below the box, 
with factor binding sites in parenthesis. 
All constructs use the I1:2 promoter ex- 
cept DS CAT, which uses the y  fibri- 
nogen promoter. 
raise the intriguing possibility that like activation of the II.-2 
enhancer, which requires multiple transcription factor sites 
for maximal activity, maximal repression may also involve 
interaction of the GR with more than a single factor and/or 
binding site. 
NFI1,2A  and  NFI1,2B  Sites  Bind  Similar  AP-l-related 
Factors.  As presented above, glucocorticoid repression occurs 
through both the NFIL-2A and NFIL-2B sites (Fig. 3 B). Be- 
cause the NFIL-2B site contains an AP-l-like sequence, we 
investigated whether the NFIL-2A site also might contain 
a similar sequence. Comparison of the NFIL-2A and NFIb 
2B sequences with a consensus AP-1 sequence (Fig. 4 A) re- 
veals the presence of the 6/7-bp match in the NFII.,2B se- 
quence and a 5/7-bp match in the NFIL-2A sequence. This 
region of the NFIb2A sequence lies immediately upstream 
from an octamer site and binds a recently discovered induc- 
ible factor,  octamer-associated protein (OAP)  (43).  Cooc- 
cupancy by Oct1 and OAP of the NFIL-2A oligonucleotide 
can be observed in a gel mobility shift. To test the possibility 
that OAP may be similar to the factor that binds to NFIb2B 
site, we ran a series of electrophoretic mobility shift assays 
using nuclear extracts from stimulatedjurkat cells. The three 
oligonucleotides,  OAP,  NFIL-2B,  and  a  consensus  AP-1 
binding site, give rise to retarded bands with similar mobili- 
ties (Fig. 4 B). In addition, both the OAP and NFIL-2B sites 
cross-compete with the consensus AP-1 site, while the un- 
related sequence, NF-AT, does not compete. Fig.  4 B, lane 
17, shows that the AP-1 site specifically competes the OAP- 
containing band and not the band containing Octl only. These 
results suggest that OAP and the factor that binds to the 
NFIL-2B site are highly related or even identical and have 
binding specificities similar to AP-1. As negative regulation 
of the IL-2 enhancer appears  to occur through interactions 
with these factors, a family of AP-l-related proteins are likely 
capable of being negatively regulated by glucocorticoids. 
Critical Factors  for 11,2 Enhancer Function Are Unaltered by 
Clucocorticoid Treatment.  The results above led us to predict 
that glucocorticoid treatment of sensitive (GR-containing) 
T lymphocytes during mitogenic stimulation would not alter 
the intrinsic properties or quantities of various factors involved 
in IL-2 transcription.  To test this hypothesis we used the 
glucocorticoid-sensitive routine T  cell line, LBRM,  which 
like jurkat cells produces Ib2 when mitogenically stimulated. 
LBRM cells were stimulated in the presence or absence of 
dexamethasone and nuclear extracts tested for factor binding 
by gd shift. The constitutive factor Oct1 and the inducible 
factors binding to an AP-1,  an NF-AT,  and the OAP sites 
are all unaffected either quantitatively or qualitatively by dexa- 
methasone treatment in vivo (Fig.  5). These results indicate 
that glucocorticoid treatment does not act indirectly by in- 
1240  Glucocorticoid Repression  of the Interleukin  2 Enhancer Figure 4.  Gel mobility  shift analysis  using AP-related sequences  within the 1I.-2 enhancer. (A) Sequence  comparison of the AP1 like sequences  within 
the NFIb2B and NFIL-2A sites with a consensus AP-1 site. The actual oligonucleotides  containing these sequences  and used for gel shifts are described 
in Material and Methods. (B) Gel mobility  shifts using labeled  oligonucleotide  probes  as shown  and nuclear extracts from PMA plus ionomydn-stimulated 
jurkat cells. Competitor oligonudeotides are none (lanes I,  6,  11,  and 16),  AP-1 (lanes 2,  7,  12,  and 17), NFID2B (lanes 3,  8,  13,  and 18),  OAP 
(lanes 4,  9,  14,  and 19),  and NF-AT (lanes 5,  10,  15,  and 20). 
hibiting synthesis of these transcription factors. Direct inter- 
actions between the GR and other transcription  factors are 
not assayable in this experiment,  as the method used to pre- 
pare the nuclear extracts does not recover GR and, therefore, 
the extracts used are essentially devoid of GR by either gel 
shift  or Western  analysis  (data  not  shown). 
Discussion 
We have presented a series of studies aimed at defining the 
mechanism by which the GR inhibits II:2 transcription.  Our 
initial findings using transgenic mice show that a stably in- 
tegrated  construct  containing  600 bp of IL-2 upstream  se- 
quence is repressible by glucocorticoid treatment to the same 
extent  as  the  endogenous  murine  I1:2  gene (Fig.  1).  This 
confirms results presented using transient  transfections (22) 
and demonstrates that the I1:2 enhancer mediates repression 
not only in a lymphoblastoid T  cell line but also in spleno- 
cytes. Importantly,  the results indicate that  transient  trans- 
fection methods are a valid approach for further analysis  of 
glucocorticoid inhibition of I1:2 gene expression. We show, 
further, that the minimal 11:2 enhancer/promoter,  containing 
only 325 bp of upstream sequence, is capable of glucocorti- 
coid repression. The comparison between the whole I1:2 en- 
hancer and the three NF-AT sites in Fig.  1 B has the caveat 
that the reporter transcripts are not the same.  It is therefore 
possible that the differences seen reflect transgene expression 
differences rather  than  enhancer  construct  differences.  Our 
results using the CAT reporter gene in transient transfections, 
however, corroborate these results showing a large difference 
between the negative regulation of the intact enhancer and 
the  multimerized  NF-AT  sites. 
While  the  inhibition  of IL2  message  accumulation  in 
splenocytes is only slightly over 50%, inhibition of reporter 
gene activity in transient assays is far greater (Figs.  1-3). This 
suggests the possibility of a translational  component to the 
reporter gene regulation,  however, this is unlikely since the 
construct containing  NFKB sites  shows no inhibition  (Fig. 
3 B). In addition,  the lack of hormone-mediated inhibition 
of the NFKB construct argues against  an effect on reporter 
gene mRNA stability. The likely explanation  for the more 
complete inhibition  seen in jurkat  cells  as compared with 
splenocytes may to be a limitation in the number of receptors 
per cell. We have found that expression of wild-type GR from 
a more active promoter in jurkat  cells leads to even greater 
inhibition (data not shown). Likewise, Vacca et al. (22) found 
that  inhibition  of I1:2-driven  CAT expression could be in- 
creased even in steroid-sensitivejurkat cells by cotransfection 
of a GR expression vector. However, it is still possible that 
mechanisms other than repression of transcription contribute 
to glucocorticoid-mediated downregulation  of I1:2 expres- 
sion.  I1:2 production  from rat  spleen cells or human  PBLs 
can be almost completely inhibited by 24 or 48 h dexametha- 
sone treatment (20) and, therefore, glucocorticoids may also 
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sensitive LBRM cells. LBRM cells were not stimulated  (N) or stimulated 
for 3 h with PMA plus ionomycin  in the presence (S  +  D) or absence 
(S) of dexamethasone  and nuclear extracts  prepared.  Gel mobility shifts 
were  done using the indicated  probes. 
have an effect on I1:2 mKNA stability,  as was found for the 
I1:1B gene (5), I1:2 mKNA translation, or I1:2 protein sta- 
bility. 
A number of our results suggest strongly that glucocorti- 
coid inhibition of IL-2 transcription is not mediated by in- 
direct pathways. First, dexamethasone treatment of GK con- 
taining LBRM cells does not inhibit production of critical 
transcription  factors  involved  in  IL-2 enhancer  function. 
Second, inhibition of I1:2 message accumulation can still be 
observed when hormone is added after the time when these 
same factors and I1:2 message become apparent. Third, the 
DNA binding specificity of the receptor can be altered to 
that  of the estrogen or  thyroid receptors without  loss  of 
repressor function, indicating that induction of a second gene, 
presumably through the interaction of the receptor with a 
GRE,  cannot be occurring. 
Deletion and mutation analysis of the GR protein reveals 
that the structural requirements for activation and repression 
are different. The NH~-terminal half, which contains a tran- 
scriptional  activation domain,  is dispensible in repression. 
Similar results have been found for GR repression of the HCG 
(40) and collagenase (14) genes. As with transcriptional acti- 
vation, an intact DNA binding domain is essential for repres- 
sion, as a single point mutation in this domain renders the 
receptor essentially inactive as a repressor. However, this does 
not mean that binding to DNA is required for repression, 
but only indicates that some critical function of the DNA 
binding domain can be lost by mutation.  Indeed, we have 
been unable to show binding of a bacterially expressed GR 
DNA binding domain, which binds well to a consensus GRE 
in vitro, to the OAP or NFI1:2B sites identified as function- 
ally important regions in glucocorticoid repression (data not 
shown).  Our  observation  that  receptors  with  the  DNA 
binding specificity of the ER or TR both work as efficient 
repressors supports the view that DNA binding is not re- 
quired. We therefore favor a mechanism by which the GR 
interacts directly with transcription factors. Likely, the overall 
structure of the zinc finger motifs within the required DNA 
binding domain needs to be maintained for receptor interac- 
tions with other factors. Our data are consistent with previous 
observations indicating that the DNA binding domain is neces- 
sary for repression of the collagenase (14) and HCG (40) genes. 
We have shown that  the hormone binding domain of the 
receptor need not be that of the GR for I1:2 repression. In 
fact,  the wild-type ER  functions as  a  reasonably efficient 
repressor in response to estradiol. Previous studies in other 
repression systems (14, 40) have shown that the GR hormone 
binding domain can be replaced functionally by that of the 
retinoic acid or mineralocorticoid receptors or even/~-galacto- 
sidase.  Thus,  I1:2  repression by the GR appears  similar to 
these examples.  Deletion of a large proportion of the hor- 
mone binding domain gives rise to a constitutive repressor 
of the I1:2  enhancer, which is nearly as active as the wild- 
type receptor. This GR construct is a more efficient repressor 
than similar constructs used in other systems (14, 40), likely 
because it leaves a greater proportion of the COOH-terminal 
half of the receptor intact.  Alternatively, the requirements 
for efficient repression of the OAP factor differ somewhat 
from those of AP-1. 
Recently,  it  has been demonstrated that  functional an- 
tagonism and protein-protein interactions occur between the 
transcription  factor  AP-1  (specifically  cJun)  and  the  GR 
(12-14).  Previous studies (42) have identified two potential 
AP-1 binding sites within the II.,2 enhancer, one of which 
lies within the functionally important region, NFI1:2B (28). 
We have identified the NF1L-2B site as one region that mediates 
repression by glucocorticoids, and it is therefore possible that 
1I:2 repression by glucocorticoids occurs by interactions be- 
tween the GR  and cJun.  Interestingly, however, previous 
studies (44) have shown that the core AP-l-like sequence of 
the NFI1:2B site, AGAGTCA, does not bind cJun/Fos het- 
erodimers. It therefore seems unlikely that the factor (likely 
OAP) that binds to the NFI1:2B site contains cJun. We have 
shown that the NFI1:2A  site also  mediates repression and 
contains a sequence similar to an AP-1 binding motif. OAP, 
which mediates inducibility through the NFIb2A site, is able 
to bind to the NFI1:2B site (unlike cJun) and to a consensus 
AP-1 site (Fig.  4).  OAP is thus a candidate for a factor, dis- 
tinct from cJun, that is functionally inactivated by the GR 
during  glucocorticoid-mediated  repression  of  I1:2  tran- 
scription. 
The precedent for a family of AP-1 factors exists with the 
identification of at least three members of the Jun family and 
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apparent similarities between AP-1 and OAP, a clear func- 
tional distinction should also be emphasized.  PMA treatment 
in the absence of ionomycin does not activate the NFII~2A 
or NFIL-2B sites in vivo, while a construct containing a con- 
sensus AP-1 site is inducible with PMA alone (31). Activa- 
tion of the NFIL-2A and NFIL-2B  sites, but not the con- 
sensus AP-1 site, is sensitive to the immunosuppressive drug 
cyclosporin A (31). In addition, we have tested a number of 
antisera directed against cJun and Fos proteins and have seen 
no  crossreactivity with  the  OAP  factor  (K.  Ullman,  J. 
Northrop, and G. Crabtree, unpublished results).  We there- 
fore propose that although OAP has a binding specificity some- 
what similar to that of AP-1, it is functionally distinct from 
AP-1 and likely does not contain cJun. The identity of OAP 
is not known at this time, however, work in our laboratory 
is currently directed towards this goal. The GR is therefore 
capable of interacting with or inhibiting the activity of a va- 
riety of transcription factors. 
In summary, we have studied the mechanism of glucocor- 
ticoid inhibition of IL-2 gene expression  in T  lymphocytes 
and have identified functionally important sequences within 
the enhancer as sites of repression.  Nuclear factors that bind 
to these sites are related to but distinct from AP-1, but like 
AP-1, are targets for repression by the GR. These studies help 
explain the growth inhibitory and functional suppressive effects 
of glucocorticoid hormones on the immune system. 
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